C8..
CANCELLED SEC. 8 (6-YR)
07/24/2026
Back to search
Official data from USPTO
INZEN
This trademark appears in the official USPTO history.
Even when the status is closed, the history helps calibrate risk, avoid repeating mistakes, and define a safe naming strategy.
CANCELLED SEC. 8 (6-YR)Type: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
CANCELLED SEC. 8 (6-YR)
Case type
Application and registration
Recorded events
24
Latest update
08/18/2026
Trademark type
Word
Nice classes
5, 42
Filing date
07/25/2018
Registration date
01/14/2020
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/24/2026
Last transaction
08/18/2026
Responsible office
United States Patent and Trademark Office
Status code
710
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
09/30/2019
First use in commerce
09/30/2019
Drawing code
4
Owner type
03
Owner location
CAMBRIDGE, MA, US
Examiner
MICKLEBURGH, LINDA BOHANNON
Law office
L60
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
INZEN THERAPEUTICS, INC.
VL47, Inc.
Representatives
CHRISTINA M. LICURSI WOLF, GREENFIELD & SACKS, P.C.
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical agents and products for cellular signal modulation for treating cancerfibrotic diseasesimmune and inflammatory diseasesneurological diseasesinfectious diseasetissue degenerative diseasesregenerative medicine; therapeutic products for cellular signal modulation in the nature of chemical and biological small molecules; pharmaceutical compositions in the nature of chemical and biological small molecules for treatment of cancerfibrotic diseasesimmune and inflammatory diseasesneurological diseasesinfectious diseasetissue degenerative diseasesregenerative medicine; pharmaceutical compositions in the nature of chemical and biological molecules for cellular signal modulation
Class 42
Scientific researchpharmaceutical researchmedical research in the fields of pharmaceutical research and development and biotechnology for others; product development for others in the field of biotechnology; development of pharmaceuticals and therapeutic agents for others
Publications
History of USPTO decisions and trademark events.
24 publications found
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
01/14/2025
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
11/11/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
01/14/2020
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
12/10/2019
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
12/08/2019
SUPC
STATEMENT OF USE PROCESSING COMPLETE
11/30/2019
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
11/30/2019
IUAF
USE AMENDMENT FILED
11/21/2019
EISU
TEAS STATEMENT OF USE RECEIVED
11/21/2019
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
05/21/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/26/2019
PUBO
PUBLISHED FOR OPPOSITION
03/26/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/06/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/20/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/04/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/04/2019
ALIE
ASSIGNED TO LIE
01/29/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/23/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
11/16/2018
GNRT
NON-FINAL ACTION E-MAILED
11/16/2018
CNRT
NON-FINAL ACTION WRITTEN
11/16/2018
DOCK
ASSIGNED TO EXAMINER
11/13/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/30/2018
Continuous trademark protection
Get notified about every new filing that threatens INZEN or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.